A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis (STARSCAPE)
A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis
Sponsor: Hoffmann-La Roche
Terminated
The study was terminated by Sponsor as the futility analysis outcome indicated that the study was unlikely to meet the predefined primary objective of the study. No new safety concerns were identified.
Other terminated trials from Hoffmann-La Roche
Other Idiopathic Pulmonary Fibrosis trials with similar outcome
This PHASE3 trial investigates Idiopathic Pulmonary Fibrosis and is currently terminated or withdrawn. Hoffmann-La Roche leads this study, which shows 35 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
35 versions recorded-
Mar 2026 — Present [monthly]
Terminated PHASE3
-
Dec 2025 — Mar 2026 [monthly]
Terminated PHASE3
-
Oct 2025 — Dec 2025 [monthly]
Terminated PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
▶ Show 30 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Jun 2023 — May 2024 [monthly]
Completed PHASE3
-
May 2023 — Jun 2023 [monthly]
Completed PHASE3
-
Apr 2023 — May 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
?stanbul, Turkey (Türkiye) , Aarthus N, Denmark , Adana, Turkey (Türkiye) , Adelaide, Australia , Aichi, Japan , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Ashkelon, Israel , Athens, Greece , Atlanta, United States and 290 more locations